Longterm Followup After Tapering Mycophenolate Mofetil During Maintenance Treatment for Proliferative Lupus Nephritis

被引：16

作者：

Laskari, Katerina ^{[1
]}

Tzioufas, Athanasios G. ^{[1
]}

Antoniou, Anna ^{[2
]}

Moutsopoulos, Haralampos M. ^{[1
]}

机构：

[1] Univ Athens, Sch Med, Dept Pathophysiol, GR-11527 Athens, Greece

[2] Univ Athens, Sch Med, Dept Hyg Epidemiol & Med Stat, GR-11527 Athens, Greece

来源：

JOURNAL OF RHEUMATOLOGY | 2011年 / 38卷 / 07期

关键词：

LUPUS NEPHRITIS; MAINTENANCE TREATMENT; MYCOPHENOLATE MOFETIL; CLASSIFICATION; ERYTHEMATOSUS; THERAPY;

D O I：

10.3899/jrheum.101249

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Objective. To determine the timing for safe reduction of mycophenolate mofetil (MMF) dose during remission-maintenance therapy of proliferative lupus nephritis. Methods. The study population consisted of 44 patients evaluated retrospectively; MMF dose was empirically tapered in 18/44 patients until the latest observation. Results. Patients reducing MMF <= 18 months after remission/complete remission had a 6.8-fold/6.3-fold higher risk of relapse compared to those taking a stable dose (p = 0.001, p = 0.011, respectively). Reducing MMF later than 18 months was not associated with increased relapse rates. Conclusion. Reducing MMF > 1.5 years after remission/complete remission seems to warrant drug tapering without increased risk of disease flare in proliferative lupus nephritis. (J Rheumatol First Release April 15 2011; doi:10.3899/jrheum.101249)

引用

页码：1304 / 1308

页数：5

共 50 条

[11] The development of membranous lupus nephritis during treatment with mycophenolate mofetil for proliferative renal disease
Dalton, Kristen
Smith, Maxwell
Thurman, Joshua M.
CLINICAL KIDNEY JOURNAL, 2010, 3 (04): : 346 - 348
[12] Mycophenolate mofetil or tacrolimus compared with azathioprine in long-term maintenance treatment for active lupus nephritis
Zhang, Qianying
Xing, Peng
Ren, Hong
Chen, Xiaonong
Xie, Jingyuan
Zhang, Wen
Shen, Pingyan
Li, Xiao
Chen, Nan
FRONTIERS OF MEDICINE, 2022, 16 (05) : 799 - 807
[13] Outcomes following mycophenolate mofetil versus cyclophosphamide induction treatment for proliferative juvenile-onset lupus nephritis
Smith, E. M. D.
Al-Abadi, E.
Armon, K.
Bailey, K.
Ciurtin, C.
Davidson, J.
Gardner-Medwin, J.
Haslam, K.
Hawley, D.
Leahy, A.
Leone, V.
McErlane, F.
Mewar, D.
Modgil, G.
Moots, R.
Pilkington, C.
Ramanan, A.
Rangaraj, S.
Riley, P.
Sridhar, A.
Wilkinson, N.
Beresford, M. W.
Hedrich, C. M.
LUPUS, 2019, 28 (05) : 613 - 620
[14] Role of mycophenolate mofetil in the treatment of lupus nephritis
Grcevska, L.
Popovska, M. Milovanceva
Dzikova, S.
Ristovska, V.
Polenakovic, M.
AUTOIMMUNITY, PT B: NOVEL APPLICATIONS OF BASIC RESEARCH, 2007, 1110 : 433 - 438
[15] Addition of cyclosporine/tacrolimus for pediatric relapsed lupus nephritis during mycophenolate mofetil maintenance therapy
Mao, Youying
Yin, Lei
Huang, Hua
Zhou, Zhengyu
Chen, Tongxin
Zhou, Wei
JOURNAL OF INTERNATIONAL MEDICAL RESEARCH, 2019, 47 (01) : 105 - 113
[16] Mycophenolate mofetil for lupus nephritis
Olech, Ewa
Merrill, Joan T.
EXPERT REVIEW OF CLINICAL IMMUNOLOGY, 2008, 4 (03) : 313 - 319
[17] Mycophenolate mofetil in lupus nephritis
Ginzler, E
Aranow, C
LUPUS, 2005, 14 (01) : 59 - 64
[18] Mycophenolate mofetil in lupus nephritis
Alvarez, L
Rivera, F
Gil, CM
del Cerro, LAJ
Olivares, J
NEFROLOGIA, 2002, 22 (01): : 24 - 32
[19] Mycophenolate mofetil as maintenance therapy for proliferative lupus nephritis: a long-term observational prospective study
Laskari, Katerina
Mavragani, Clio P.
Tzioufas, Athanasios G.
Moutsopoulos, Haralampos M.
ARTHRITIS RESEARCH & THERAPY, 2010, 12 (06)
[20] Mycophenolate mofetil as maintenance therapy for proliferative lupus nephritis: a long-term observational prospective study
Katerina Laskari
Clio P Mavragani
Athanasios G Tzioufas
Haralampos M Moutsopoulos
Arthritis Research & Therapy, 12

← 1 2 3 4 5 →